Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02051309 · ClinicalTrials.gov registry record · Phase 2
Guanfacine Clinical Trial for Smoking Cessation
A Phase 2 study of Smoking Cessation, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
- 1
- Study location
NCT02051309 is a Phase 2 study of Smoking Cessation that has completed, run by Yale University. The registered enrollment target is 121 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02051309, a Phase 2 study of Smoking Cessation, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
- 1
- Study location
Study Summary
Adult daily smokers motivated to quit smoking will be randomized to extended-release guanfacine (6mg/day) or placebo and will enroll in an 8-week treatment period combining medication with brief behavioral support. The investigators hypothesize that the active dose of guanfacine compared to placebo will increase rates of prolonged smoking abstinence at the end of the 8-week treatment phase.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Guanfacine
Study Locations (1)
Connecticut
- Yale Center for Clinical Investigations, Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2014-03 |
| Est. Completion | 2020-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02051309
The ClinicalTrials.gov registry entry for NCT02051309 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (74% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02051309 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02051309 about?
NCT02051309 is a clinical study titled "Guanfacine Clinical Trial for Smoking Cessation". Adult daily smokers motivated to quit smoking will be randomized to extended-release guanfacine (6mg/day) or placebo and will enroll in an 8-week treatment period combining medication with brief behavioral support. The investigators hypothesize that the active dose of guanfacine compared to placebo ...
What is the current status of trial NCT02051309?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2014-03. Estimated completion is 2020-11.
What conditions does trial NCT02051309 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT02051309?
The interventions under investigation include: Placebo (DRUG), Guanfacine (DRUG).
Who is sponsoring clinical trial NCT02051309?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02051309 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
RECRUITING · Phase 2
-
Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate
COMPLETED · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Suvorexant to Reduce Symptoms of Nicotine Use
COMPLETED · Phase 2
-
Pharmacogenetics, Emotional Reactivity and Smoking
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.